Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat.
about
Modulation of glucose metabolism by the renin-angiotensin-aldosterone systemNarrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.Skeletal muscle insulin resistance in endocrine disease.Aldosterone: role in the cardiometabolic syndrome and resistant hypertensionImpact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodelingAldosterone and inflammation.Monoclonal antibody to six transmembrane epithelial antigen of prostate-4 influences insulin sensitivity by attenuating phosphorylation of P13K (P85) and Akt: possible mitochondrial mechanism.Effects of aldosterone on insulin sensitivity and secretion.Beneficial effects of calcitriol on hypertension, glucose intolerance, impairment of endothelium-dependent vascular relaxation, and visceral adiposity in fructose-fed hypertensive rats.Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation.Exercise in the metabolic syndrome.Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.Loss of Estrogen Receptor α Signaling Leads to Insulin Resistance and Obesity in Young and Adult Female Mice.Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterationsDifferential predictors of insulin resistance in nondiabetic salt-resistant and salt-sensitive subjects.Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in miceThe Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle.Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression.Increased insulin sensitivity in mice lacking collectrin, a downstream target of HNF-1alpha.Low aerobic capacity and high-fat diet contribute to oxidative stress and IRS-1 degradation in the kidney.The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress.Type 2 diabetes mellitus and hypertension: an update.The role of aldosterone in the metabolic syndrome.Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?The renin-angiotensin-aldosterone system and glucose homeostasis.The renin-angiotensin system in the pathophysiology of type 2 diabetes.Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus.Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat.Aldosterone aggravates glucose intolerance induced by high fructose.Ultrastructure Study of Transgenic Ren2 Rat Aorta - Part 1: Endothelium and IntimaHypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β-cells.Impact of Adrenal Steroids on Regulation of Adipose Tissue.Low-dose spironolactone ameliorates insulin resistance and suppresses elevated plasminogen activator inhibitor-1 during gestational testosterone exposure.Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.Emerging Role of Aldosterone in Mediating the Vicious Cycle of Obesity, Insulin Resistance and Metabolic Syndrome.
P2860
Q27026157-2B761DA3-EEBB-4674-833C-4714D3ADD1E8Q33667283-681FA009-8962-4A1A-9A5C-AF5507CE1C95Q33734293-0048C206-A980-4A92-BE2F-E4E5ABFDF97FQ33736838-50CAA19C-6449-4923-BF01-7C0E1E358481Q33775560-DBB1A463-C68A-4BFF-AC97-3532653E8F1EQ33837784-44424817-35EF-4319-BB03-46C46959E71AQ33925412-FE414C60-FA5E-4115-98A2-AABB6C3140DCQ34614820-96C2AF0A-1B31-4FD6-A8BB-F07B8B66C9EBQ35182438-B9BF75C9-1391-443D-8272-5F42D113F8E9Q35551235-E4C9B0B5-F82A-47FD-9D21-1D00FA297FD5Q35916243-E79057C8-F1C4-4DF9-AB19-A6EB1301D40BQ35924401-19B28535-4FB4-4D7C-A2B6-1EAD0EDB8371Q36102382-48DE1790-9E65-44B5-942A-8327F09CC4D6Q36106582-25B0E103-5AD4-41EC-A145-0198D1B2103AQ36171304-FC605432-BBA0-4109-A81E-784B7C99E9FEQ36206183-5CD916B6-FBAC-40A8-9D79-A7F7B20242FBQ36297722-A1652AF7-8E54-4107-8C4F-77167CA4E43FQ36665733-BA984925-0350-4B5B-9DCE-B98FD928D2C2Q36672857-D62AD0E7-6AD2-4723-A0B9-9932E75168E9Q37039767-6768FE47-7057-49B4-91DC-663563AB60F2Q37190283-DE6FC601-8980-427B-B7D5-21B11777E9C8Q37210815-F3782823-93CD-46B8-B908-D104507E2F67Q37214981-8C7F3C71-412A-4CF2-B841-7CA445E0DFC6Q37449584-797067A1-692D-4DDB-B200-39D0463BFA65Q37475546-B6F94657-3A4F-4858-9B84-5290E4050207Q37617567-FC48CC0E-881B-43FE-8338-209AFCA0173AQ37833554-C7A5372C-09BF-4852-A29C-BF534D658259Q37893694-939B2F98-113A-4105-B74D-7984708DB5EFQ37924374-099830DE-A440-470F-83E3-8D9642C20CE9Q38044215-25D414F7-BE1B-4988-A349-7DACE37C5F36Q38354900-CE1CB451-9B61-4511-B903-54361BEAA00EQ38367410-EF278669-017E-41C8-95B9-C2D5B27690F7Q41848157-F8ADB48D-DDEE-470E-B078-4758678C5DABQ41873243-F6BD7A4C-67E6-47F3-AC9A-980703991771Q42111982-0FACB4AC-0BA4-4B56-8D05-C26EDB6D668EQ50068164-333E7EF8-507A-41DF-B5DB-E4C86566A189Q50247258-A07727B6-C866-4E50-BD37-E7DB14E271EFQ51358591-6DD95615-C2CD-4A4D-AF9B-F4F1E3F36169Q53700741-3901FC11-4AC5-4E7F-8A2D-AFE680BF5AD7
P2860
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@ast
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@en
type
label
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@ast
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@en
prefLabel
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@ast
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@en
P2093
P2860
P1476
Low-dose spironolactone reduce ...... muscle in the TG(mRen2)27 rat.
@en
P2093
Adam Whaley-Connell
Alex A Gutweiler
Camila Manrique
Carlos Ferrario
Guido Lastra
James R Sowers
Javad Habibi
Lama Appesh
Melvin R Hayden
Yongzhong Wei
P2860
P304
P356
10.1152/AJPENDO.00258.2007
P577
2008-04-29T00:00:00Z